Comparative Pharmacology
Head-to-head clinical analysis: MIRAPEX versus MIRAPEX ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRAPEX versus MIRAPEX ER.
MIRAPEX vs MIRAPEX ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
None Documented
None Documented
The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function.
Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min).
Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%).
Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal.
Category C
Category C
Dopamine Agonist
Dopamine Agonist